CANbridge Forms Scientific Advisory Board to Guide Global Development of CAN106 in Complement-mediated Diseases
CAN106 Phase 1 results showed rapid and potent C5 inhibition, complete and sustained blockade of complement activity Data presented at European Hematology Association 2022 Congress and 14th International Conference on Complement Therapeutics CAN106 in Phase 1b/2 study of paroxysmal nocturnal hemoglobinuria in China Shows potential for treating other complement-mediated diseases BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge … [Read more…]
